Search hospitals > Illinois > Chicago
Great Lakes Clinical Trials
Claim this profileChicago, Illinois 60640
Global Leader in Alzheimer's Disease
Global Leader in COVID-19
Conducts research for Arthritis
Conducts research for Obesity
Conducts research for Coronavirus
105 reported clinical trials
4 medical researchers
Summary
Great Lakes Clinical Trials is a medical facility located in Chicago, Illinois. This center is recognized for care of Alzheimer's Disease, COVID-19, Arthritis, Obesity, Coronavirus and other specialties. Great Lakes Clinical Trials is involved with conducting 105 clinical trials across 102 conditions. There are 4 research doctors associated with this hospital, such as Manish Jain, Jeffrey Ross, MD, Rupal Pravin Trivedi, and Rupal Trivedi.Top PIs
Manish JainGreat Lakes Clinical Trials - Ravenswood1 year of reported clinical research
Studies Obesity
Studies Arthritis
18 reported clinical trials
20 drugs studied
Jeffrey Ross, MDGreat Lakes Clinical Trials - Andersonville2 years of reported clinical research
Studies Alzheimer's Disease
Studies Memory Loss
5 reported clinical trials
8 drugs studied
Rupal Pravin TrivediGreat Lakes Clinical Trials - Andersonville1 year of reported clinical research
Studies Obesity
3 reported clinical trials
4 drugs studied
Rupal TrivediGreat Lakes Clinical Trials - Andersonville1 year of reported clinical research
Studies Obesity
Studies Diabetes
1 reported clinical trial
2 drugs studied
Clinical Trials running at Great Lakes Clinical Trials
Obesity
Gout
Alzheimer's Disease
Cardiovascular Disease
Arthritis
Chronic Kidney Disease
Type 2 Diabetes
Diabetes
Depression
High Cholesterol
CagriSema vs. Tirzepatide
for Weight Loss in Obesity
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.
Recruiting2 awards Phase 33 criteria
Orforglipron
for Type 2 Diabetes and Obesity
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Recruiting2 awards Phase 3
Retatrutide
for Obesity
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Recruiting1 award Phase 32 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Great Lakes Clinical Trials?
Great Lakes Clinical Trials is a medical facility located in Chicago, Illinois. This center is recognized for care of Alzheimer's Disease, COVID-19, Arthritis, Obesity, Coronavirus and other specialties. Great Lakes Clinical Trials is involved with conducting 105 clinical trials across 102 conditions. There are 4 research doctors associated with this hospital, such as Manish Jain, Jeffrey Ross, MD, Rupal Pravin Trivedi, and Rupal Trivedi.